Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Anticancer Res ; 41(5): 2467-2471, 2021 May.
Article in English | MEDLINE | ID: mdl-33952472

ABSTRACT

BACKGROUND/AIM: Adaptive radiation therapy (ART) is a technique capable of reducing radiation dose to normal tissue without compromising local control. For potentially resectable thymoma, induction therapy is standard of care. Because large disease volume is common in this context, ART has been suggested to reduce toxicity from induction chemoradiation. This has not been previously illustrated in the literature. CASE REPORT: A 38-year-old man with initially unresectable thymoma was treated with induction chemoradiation including cisplatin and etoposide. He received 45 Gy in 25 fractions and ART was utilized to shrink the radiotherapy field for the final 10 fractions. RESULTS: Thymectomy showed Masaoka stage III disease with negative margins. He experienced no treatment-related toxicity and has no evidence of disease 8 years after diagnosis. CONCLUSION: Induction chemoradiotherapy with ART appears to be feasible, safe, and efficacious for locally advanced intact thymoma.


Subject(s)
Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/radiotherapy , Thymoma/drug therapy , Thymoma/radiotherapy , Adult , Cisplatin/therapeutic use , Combined Modality Therapy , Etoposide/therapeutic use , Humans , Male , Neoplasm Recurrence, Local/pathology , Thymoma/pathology
2.
J Investig Med ; 67(2): 295-302, 2019 02.
Article in English | MEDLINE | ID: mdl-30530528

ABSTRACT

Survivors of childhood brain tumors may be at risk for early onset of metabolic syndrome, possibly secondary to surgery and/or radiation exposure. This study examines effects of radiation exposure to hypothalamus-pituitary-adrenal axis (HPA) on metabolic risk among survivors of childhood brain tumors. One hundred forty-two met inclusion criteria; 60 had tumor surgery plus radiation exposure (>1 Gray (Gy)) to HPA. The second subgroup of 82 subjects had surgery only and were not exposed to radiation. Both subgroups had survived for approximately 5 years at the time of study. All had clinical evaluation, vital signs, anthropometry, measurement of body composition by dual X-ray absorptiometry and fasting laboratory assays (metabolic panel, insulin, C-peptide, insulin-like growth factor-1, leptin and adiponectin). Body composition data for both subgroups was compared with the National Health and Nutrition Survey (NHANES) subgroup of similar age, gender and body mass index. Cranial surgery was associated with obesity of similar severity in both subgroups. However, survivors exposed to radiation to the HPA also had increased visceral fat mass and high prevalence of growth hormone deficiency and metabolic syndrome. Fat mass alone did not explain the prevalence of the metabolic syndrome in radiation exposure subgroup. Other factors such as growth hormone deficiency may have contributed to metabolic risk. We conclude that prevalence of metabolic syndrome among subjects exposed to hypothalamic radiation was higher than expected from hypothalamic obesity alone. Radiation exposure may exert untoward endocrinopathies due to HPA exposure that worsens metabolic risk. Early screening for metabolic syndrome in this population is indicated.


Subject(s)
Brain Neoplasms/complications , Brain Neoplasms/radiotherapy , Cancer Survivors , Hypothalamus/pathology , Metabolic Syndrome/drug therapy , Metabolic Syndrome/etiology , Obesity/complications , Radiation Exposure/adverse effects , Adolescent , Body Composition , Child , Female , Growth Hormone/therapeutic use , Humans , Male , Phenotype , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...